Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Roche Holding’s Gazyva achieved positive Phase III results in the MAJESTY trial for primary membranous nephropathy.
The study met its primary and key secondary endpoints, with statistically significant and clinically meaningful complete remission rates versus current standard of care.
Roche plans regulatory submissions in the US and EU, aiming to position Gazyva as the first approved therapy for this rare autoimmune kidney disease.
For investors watching SWX:ROG, this update comes with the shares at CHF361.4 and recent momentum, with the stock up 2.1% over the past week, 3.6% over the past month and 11.0% year to date. Over 1 year, Roche is up 26.9%, and over 3 and 5 years the stock has returned 44.0% and 40.8% respectively. This provides context for assessing how new clinical data might influence sentiment around the company.
The Gazyva data relates to Roche’s effort to expand its product portfolio into areas of high unmet need, in this case a serious autoimmune kidney disease affecting tens of thousands of patients. As Roche prepares to present the MAJESTY results at medical meetings and seek approvals in the US and EU, investors will be watching how regulators respond and how quickly this potential first in class therapy might move through the review process.
Stay updated on the most important news stories for Roche Holding by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Roche Holding.
SWX:ROG Earnings & Revenue Growth as at Feb 2026
We’ve flagged 1 risk for Roche Holding. See which could impact your investment.
For Roche, Gazyva’s MAJESTY readout speaks directly to the size and quality of its nephrology franchise rather than just a one off data point. Primary membranous nephropathy affects an estimated 184,000 people across the US and EU, and current treatments rely on drugs like tacrolimus that were not designed specifically for this disease. A drug that can deliver higher complete remission rates with no new safety concerns gives Roche a chance to set the treatment standard in a niche but high-need indication. It also reinforces the idea that Gazyva is more than an oncology product, building on prior positive Phase III results in lupus nephritis, systemic lupus erythematosus and idiopathic nephrotic syndrome. Investors comparing Roche with peers such as Novartis, Sanofi or AstraZeneca may see this as incremental evidence that Roche’s immunology and kidney-disease pipeline is productive and less tied to any single therapy area.
The MAJESTY success supports the narrative that Roche’s high value biologics pipeline can broaden into immune mediated and kidney diseases, helping diversify away from older, patent sensitive products.
It also highlights execution risk, since the broader narrative already flags that late stage trials can underperform and that not every asset will progress smoothly through regulators.
The potential for Gazyva to span multiple immune mediated indications, including primary membranous nephropathy and lupus nephritis, adds breadth that is only partially captured in a simple discussion of pipeline depth.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Roche Holding to help decide what it is worth to you.
⚠️ Regulatory review in the US and EU could take time or result in label restrictions, which would limit how widely Gazyva is used in primary membranous nephropathy.
⚠️ Analysts have flagged one key risk related to Roche’s financial position, and adding another indication for Gazyva may require further investment in trials, physician education and access programs.
🎁 If approved, Gazyva would be the first therapy specifically indicated for primary membranous nephropathy, giving Roche a first mover position in a rare autoimmune kidney disease.
🎁 MAJESTY is the fourth positive Phase III study for Gazyva in immune mediated diseases, which supports the idea that Roche can build a broader renal and immunology franchise from a single antibody platform.
From here, the key checkpoints are the detailed MAJESTY data at upcoming medical meetings and feedback from the US Food and Drug Administration and European Medicines Agency. You will want to see whether regulators focus on the complete remission data, the duration of response and the safety profile compared with tacrolimus. It is also worth watching how Roche talks about Gazyva’s positioning across kidney and autoimmune indications on future earnings calls, especially relative to competitors like Novartis and AstraZeneca that are also active in immune disorders. Pricing, reimbursement decisions and any comments on demand from nephrologists will help clarify how material this indication could become over time.
To ensure you’re always in the loop on how the latest news impacts the investment narrative for Roche Holding, head to the community page for Roche Holding to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROG.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com